{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:21:46Z","timestamp":1759335706295},"reference-count":4,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.vaccine.2005.12.003","type":"journal-article","created":{"date-parts":[[2005,12,20]],"date-time":"2005-12-20T10:21:35Z","timestamp":1135074095000},"page":"2223-2224","source":"Crossref","is-referenced-by-count":3,"title":["How far can the antigen content of tissue culture rabies vaccine be reduced safely?"],"prefix":"10.1016","volume":"24","author":[{"given":"Jiri","family":"Beran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Honegr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Banzhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudius","family":"Malerczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2005.12.003_bib1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.vaccine.2005.10.013","article-title":"How far can the antigen content of tissue culture rabies vaccine be reduced safely?","volume":"24","author":"Wilde","year":"2006","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2005.12.003_bib2","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.vaccine.2005.03.007","article-title":"Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine","volume":"23","author":"Beran","year":"2005","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2005.12.003_bib3","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2004.09.027","article-title":"Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals","volume":"23","author":"Quiambao","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2005.12.003_bib4","series-title":"WHO expert consultation on rabies: first report","author":"WHO","year":"2004"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05012259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05012259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T07:58:44Z","timestamp":1547884724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X05012259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":4,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0264410X05012259"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2005.12.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}